Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor

This publication has 22 references indexed in Scilit:

• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
  New England Journal of Medicine, 2018
• Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• Genomic Features of Response to Combination Immunotherapy in Lung Cancer
  Cancer Cell, 2018
• The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients
  International Journal of Gynecological Cancer, 2017
• Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
  Clinical Cancer Research, 2016
• The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
  Oncotarget, 2015
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
  The Lancet Oncology, 2014
• Roles of Chk1 in cell biology and cancer therapy
  International Journal of Cancer, 2013
• Checkpoint kinase 1 in DNA damage response and cell cycle regulation
  Cellular and Molecular Life Sciences, 2013
• Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?
  Cancer Science, 2012